Literature DB >> 33316460

Successful pregnancy in the setting of eosinophil depletion by benralizumab.

Scott Manetz1, Irina Maric2, Thomas Brown3, Fei Li Kuang4, Lauren Wetzler3, Elizabeth Battisto5, Amy D Klion6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33316460      PMCID： PMC8377677          DOI： 10.1016/j.jaip.2020.11.060

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.

Authors:  Fei Li Kuang; Fanny Legrand; Michelle Makiya; JeanAnne Ware; Lauren Wetzler; Thomas Brown; Tamika Magee; Brent Piligian; Pryscilla Yoon; Jamie H Ellis; Xiaoping Sun; Sandhya R Panch; Astin Powers; Hawwa Alao; Sheila Kumar; Martha Quezado; Li Yan; Nancy Lee; Roland Kolbeck; Paul Newbold; Mitchell Goldman; Michael P Fay; Paneez Khoury; Irina Maric; Amy D Klion
Journal:  N Engl J Med       Date:  2019-04-04       Impact factor: 91.245

2.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

Authors:  William W Busse; Eugene R Bleecker; J Mark FitzGerald; Gary T Ferguson; Peter Barker; Stephanie Sproule; Richard F Olsson; Ubaldo J Martin; Mitchell Goldman
Journal:  Lancet Respir Med       Date:  2018-11-08       Impact factor: 30.700

3.  Eosinophils are required for the maintenance of plasma cells in the bone marrow.

Authors:  Van Trung Chu; Anja Fröhlich; Gudrun Steinhauser; Tobias Scheel; Toralf Roch; Simon Fillatreau; James J Lee; Max Löhning; Claudia Berek
Journal:  Nat Immunol       Date:  2011-01-09       Impact factor: 25.606

4.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma.

Authors:  William W Busse; Rohit Katial; David Gossage; Suha Sari; Bing Wang; Roland Kolbeck; Anthony J Coyle; Masamichi Koike; George L Spitalny; Peter A Kiener; Gregory P Geba; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

5.  MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function.

Authors:  Roland Kolbeck; Alexander Kozhich; Masamichi Koike; Li Peng; Cecilia K Andersson; Melissa M Damschroder; Jennifer L Reed; Robert Woods; William W Dall'acqua; Geoffrey L Stephens; Jonas S Erjefalt; Leif Bjermer; Alison A Humbles; David Gossage; Herren Wu; Peter A Kiener; George L Spitalny; Charles R Mackay; Nestor A Molfino; Anthony J Coyle
Journal:  J Allergy Clin Immunol       Date:  2010-06       Impact factor: 10.793

6.  Peripheral blood eosinophilia in infants at 3 months of age is associated with subsequent development of atopic disease in early childhood.

Authors:  M P Borres; H Odelram; K Irander; N I Kjellman; B Björkstén
Journal:  J Allergy Clin Immunol       Date:  1995-03       Impact factor: 10.793

7.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Authors:  Mario Castro; Sally E Wenzel; Eugene R Bleecker; Emilio Pizzichini; Piotr Kuna; William W Busse; David L Gossage; Christine K Ward; Yanping Wu; Bing Wang; Deepak B Khatry; René van der Merwe; Roland Kolbeck; Nestor A Molfino; Donald G Raible
Journal:  Lancet Respir Med       Date:  2014-10-08       Impact factor: 30.700

8.  Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial.

Authors:  Pamela L Zeitlin; Mila Leong; Jeremy Cole; Raburn M Mallory; Vivian H Shih; Richard F Olsson; Mitchell Goldman
Journal:  J Asthma Allergy       Date:  2018-11-20

9.  Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.

Authors:  Li Yan; Bing Wang; Yen Lin Chia; Lorin K Roskos
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447
  9 in total
  5 in total

Review 1.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

2.  Eosinophils are an essential element of a type 2 immune axis that controls thymus regeneration.

Authors:  Emilie J Cosway; Andrea J White; Sonia M Parnell; Edina Schweighoffer; Helen E Jolin; Andrea Bacon; Hans-Reimer Rodewald; Victor Tybulewicz; Andrew N J McKenzie; William E Jenkinson; Graham Anderson
Journal:  Sci Immunol       Date:  2022-03-11

3.  Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.

Authors:  Adel H Mansur
Journal:  Respir Med Case Rep       Date:  2021-11-27

4.  Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells.

Authors:  Sisi Chen; Gaoying Chen; Fang Xu; Beibei Sun; Xinyi Chen; Wei Hu; Fei Li; Madiha Zahra Syeda; Haixia Chen; Youqian Wu; Peng Wu; Ruirui Jing; Xinwei Geng; Lingling Zhang; Longguang Tang; Wen Li; Zhihua Chen; Chao Zhang; Jie Sun; Wei Chen; Huahao Shen; Songmin Ying
Journal:  Cell Discov       Date:  2022-08-16       Impact factor: 38.079

Review 5.  Recent advances in understanding the role of eosinophils.

Authors:  Gregory M Constantine; Amy D Klion
Journal:  Fac Rev       Date:  2022-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.